Nifty Pharma gains 14.5% YTD on defensive investor shift
Indian pharmaceutical stocks are surging this year as investors flee broader market volatility, though analysts warn the sector is currently overextended and ripe for a correction.
The Nifty Pharma index has surged 14.53% year-to-date, sharply contrasting with a 7.87% decline in the broader Nifty 50 benchmark. This divergence underscores a pronounced market shift toward defensive sectors as macroeconomic and geopolitical uncertainties weigh on risk appetite.
Foreign portfolio investors have pulled capital from Indian equities amid escalating Middle East tensions, rising crude oil prices, and persistent inflation concerns. Weakness in heavyweight financial, IT, and energy stocks has further dragged down the benchmark, while elevated domestic valuations and an unclear US Federal Reserve policy outlook have amplified institutional caution.
Pharmaceutical companies are providing the earnings stability that investors currently demand. Sunny Agrawal, Head of Fundamental Research at SBI Securities, said "the June quarter is likely to witness healthy year-on-year revenue growth for most pharmaceutical companies, led by sustained strength in the domestic formulations (DF) business." This domestic resilience is supported by a post-GST recovery and steady demand in speciality healthcare segments.
The outlook for Indian pharma's US operations remains fractured. "New product launches and better operational execution should support US revenues, but the base business could remain under pressure due to lower generic Revlimid sales and continued pricing erosion in select generic segments," Agrawal noted. Consequently, he argued "domestic formulations will remain the primary earnings driver for the sector in the near term."
Chart indicators reinforce the sector's robust momentum. Sudeep Shah, Head of Technical and Derivatives Research at SBI Securities, observed that "the Nifty Pharma index continues to exhibit a higher-high, higher-low pattern, reaffirming the prevailing bullish trend." He added that "The index is trading comfortably above its key short- and long-term moving averages, indicating sustained buying momentum."
However, the speed of the rally has triggered technical caution. Hitesh Rathi, Technical Analyst at Angel One, warned that "the sharp rally has pushed the index well above its key moving averages, making it somewhat stretched in the near term." He advised that "investors may be better served by waiting for either a healthy price correction or a period of consolidation before initiating fresh positions."
Traders are watching the 25,300-25,350 zone as a critical floor. Shah noted that "the 25,300-25,350 zone, which coincides with the previous swing low and the 20-day exponential moving average (EMA), is likely to act as a crucial support level." As long as the index holds above this threshold, the broader upward trajectory remains intact.
Looking ahead, analysts expect further share price appreciation to come from actual profit growth rather than multiple expansions. Agrawal highlighted Sun Pharma, Ajanta Pharma, Alkem Laboratories, Divi's Laboratories and Zydus Lifesciences as preferred long-term picks. Expanding global outsourcing opportunities in the CDMO and API segments should provide additional structural tailwinds for these names.
